CD274 and non-small cell lung carcinoma: According to the European Society of Medical Oncology (ESMO) and the National Comprehensive Cancer Network (NCCN) guidelines, PD-1/PD-L1 inhibitors are recommended as first-line monotherapy treatment only for NSCLC patients with ≥50% PD-L1 expression and no other actionable molecular markers, while ICI treatment for NSCLC patients with 1–49% PD-L1 expression is only recommended as first-line therapy if in conjunction with a platinum-based chemotherapeutic agent and Pemetrexed or as second-line monotherapy treatment [24,25].